By Application
Hot products 
-
Mouse Anti-ATP5F1A Recombinant Antibody (51) (CBMAB-A4043-YC)
-
Mouse Anti-B2M Recombinant Antibody (CBYY-0050) (CBMAB-0050-YY)
-
Mouse Anti-ADGRL2 Recombinant Antibody (V2-58519) (CBMAB-L0166-YJ)
-
Mouse Anti-ARHGDIA Recombinant Antibody (CBCNA-009) (CBMAB-R0415-CN)
-
Mouse Anti-DLC1 Recombinant Antibody (D1009) (CBMAB-D1009-YC)
-
Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY)
-
Rabbit Anti-Acetyl-Histone H4 (Lys16) Recombinant Antibody (V2-623415) (CBMAB-CP1021-LY)
-
Mouse Anti-EPO Recombinant Antibody (CBFYR0196) (CBMAB-R0196-FY)
-
Mouse Anti-CD46 Recombinant Antibody (CBFYC-0076) (CBMAB-C0085-FY)
-
Mouse Anti-AFM Recombinant Antibody (V2-634159) (CBMAB-AP185LY)
-
Mouse Anti-BPGM Recombinant Antibody (CBYY-1806) (CBMAB-2155-YY)
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503417) (CBMAB-V208-1369-FY)
-
Rabbit Anti-ALDOA Recombinant Antibody (D73H4) (CBMAB-A2314-YC)
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
-
Mouse Anti-CRYAB Recombinant Antibody (A4345) (CBMAB-A4345-YC)
-
Mouse Anti-C1QC Recombinant Antibody (CBFYC-0600) (CBMAB-C0654-FY)
-
Mouse Anti-ARIH1 Recombinant Antibody (C-7) (CBMAB-A3563-YC)
-
Mouse Anti-CECR2 Recombinant Antibody (CBWJC-2465) (CBMAB-C3533WJ)
-
Mouse Anti-CD1C Recombinant Antibody (L161) (CBMAB-C2173-CQ)
-
Mouse Anti-GFAP Recombinant Antibody (24) (CBMAB-G2927-LY)
Breast Cancer
Fig.1 Breast cancer
Breast cancer is mainly considered to develop in cells from the lining of milk ducts and the lobules that produce the milk, which is known as ductal carcinomas and lobular carcinomas. Risk factors giving rise to breast cancer include being female, obesity, lacking of physical exercise and so on. Signs of breast cancer may include a red scaly patch of skin, a lump in the breast, a change in breast shape, dimpling of the skin or fluid coming from the nipple. About 5–10% of cases can be attributed to genes inherited from a person's parents, including BRCA1 and BRCA2 among others. The diagnosis of breast cancer can be confirmed by taking a biopsy of the concerning lump. In addition, when the diagnosis is made, further tests need to be done to determine if the cancer has spread beyond the breast and which treatments it may respond to. Clinically, the most useful metabolic markers in breast cancer are the estrogen and progesterone receptors that are used to predict response to hormone therapy. HER-2 and SCD1 predict response to therapeutic regimens, and urokinase plasminogen activators (PA1-1 and SCD1) are used for assessing prognosis.
Loading...
Compare
